[ad_1]
Johnson & Johnson’s coronavirus vaccine generated a long-lasting immune response to the deadly virus in an early-stage clinical trial, the pharmaceutical giant said.
More than 90% of the 805 study participants had neutralizing antibodies that provide protection against COVID-19 29 days after receiving a single dose of the vaccine, the New Jersey-based drugmaker said on Wednesday.
The antibodies remained for at least 71 days in participants aged 18 to 55, according to provisional results published in the New England Journal of Medicine. J&J said it will have data later this month on the durability of immunity in people over 65.
Early data showed signs of promise for the Johnson & Johnson one shot vaccine even as the company reportedly encountered a problem in producing the inoculations.
J&J said he plans to announce the results of his main late-stage vaccine trial at the end of the month. He will then ask the Food and Drug Administration to clear the shot for emergency use if the data shows it to be safe and effective.
Early safety data showed that people who had reactions to the vaccine generally improved within 24 hours, the company said. The most common side effects were headache, muscle pain, fatigue, and pain at the injection site.
The Johnson & Johnson vaccine is different from the Pfizer and Moderna vaccines distributed across the country.
Vaccines from the latter companies require two doses and use genetic material called messenger RNA to direct the body to create a tiny amount of peak coronavirus protein, triggering an immune response. Johnson & Johnson’s only requires a single dose and delivers peak proteins via a disabled cold virus that cannot infect the recipient.
J&J also studied a two-dose regimen of his vaccine and found that the second dose, given 56 days apart, “triggered more than twice as many antibodies against COVID-19,” the company said.
Johnson & Johnson shares jumped 1.7% in pre-market trading Thursday to $ 160.68 at 7:42 a.m.
[ad_2]
Source link